X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

ICER’s budget impact threshold: Sounding a false alarm on affordability and access

By Randy Burkholder  |    July 24, 2018
If a home inspector found “wide and unpredictable variation” in your smoke detectors, would you want to fix them?   Read More

PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs

By Holly Campbell  |    July 16, 2018
Today, PhRMA submitted comprehensive comments to the Department of Health and Human Services (HHS) request for information (RFI), HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs....   Read More

How ICER’s assessment of a new class of migraine treatments fails patients

By Lauren Neves  |    July 10, 2018
Over 50 million Americans suffer from migraine and the majority of patients affected by this often debilitating disease are between 25 and 55 years old – the time they are most productive in their...   Read More

Aspen Spotlight Health: Discussing the forefront of innovation

By Katie Koziara  |    June 21, 2018
For the second year in a row, PhRMA is proud to participate in Aspen’s Spotlight Health Conference. As the opening session of Aspen Ideas Festival, Spotlight Health welcomes over 1,500 experts and...   Read More

New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B

By Lauren Neves  |    May 31, 2018
Amidst debate about rising health care costs, some policy-makers have expressed renewed interest in using cost-effectiveness thresholds as the basis for setting coverage and payment policy. But a ...   Read More

ICYMI: Recent survey adds to growing body of research on barriers to innovative payment approaches

By Joe Vandigo  |    May 29, 2018
  A recent study conducted by the Academy of Managed Care Pharmacy (AMCP) and Xcenda found that 71 percent of insurers and 63 percent of biopharmaceutical companies surveyed were interested in...   Read More

Reality check: Value-based contracts are good for patients

By Michelle Drozd  |    April 25, 2018
Biopharmaceutical companies are joining stakeholders across the health care system to pursue flexible ways to pay for medicines that focus on results, lower out-of-pocket costs and enable patients...   Read More

Video: Barriers to results-based contracts

By Katie Koziara  |    April 17, 2018
Research suggests results-based contracts (RBCs)—also known as value-based contracts—have the potential to lower costs for patients and the health system. According to a recent analysis, these...   Read More

Improving care quality by engaging patients in shared decision making

By Randy Burkholder  |    March 22, 2018
With the rapid movement towards value-based payment and delivery in health care, it is critical not to leave one of the key players behind: the patient.     Read More

ICYMI: Research shows promise of innovative payment arrangements in reducing costs, improving access

By Joe Vandigo  |    March 15, 2018
To address rising health care costs and help patients better access new medicines, biopharmaceutical companies are sharing financial risk with payers through new payment arrangements, like...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates